I think we all have stopped expecting the stock price to be higher in the short-term and on expected events.
To TTMB's concern, yes, slow uptake would necessitate a capital raise. According to the CS estimates, the $35 target price already assumes a $200m raise in 2020. That would be the base case, but let's see if there is something else that management has up their sleeve to avoid a dilution. You have to think that, come next year and every subsequent year, the pressure to stock and use Andexxa is greater, and that it will become the SOC. Hopefully a dilution is priced in at these levels, and the only downside risk is not hitting expected revenues, which management has already said they are comfortable with.